Finished Dosage Form (FDF) import of Antide obtained from Indian Custom Trade Statistics

PharmaCompass

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Iturelix, 112568-12-4, Orf 23541, Nal-lys anatagonist, Orf-32541, Antide acetate
Molecular Formula
C82H108ClN17O14
Molecular Weight
1591.3  g/mol
InChI Key
QRYFGTULTGLGHU-NBERXCRTSA-N
FDA UNII
94055UOQ3Y

Antide
1 2D Structure

Antide

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[(5R)-5-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2R)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-(4-chlorophenyl)propanoyl]amino]-3-pyridin-3-ylpropanoyl]amino]-3-hydroxypropanoyl]amino]-6-(pyridine-3-carbonylamino)hexanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2R)-1-amino-1-oxopropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-6-(propan-2-ylamino)hexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-6-oxohexyl]pyridine-3-carboxamide
2.1.2 InChI
InChI=1S/C82H108ClN17O14/c1-50(2)41-65(76(108)95-64(26-11-12-37-88-51(3)4)82(114)100-40-18-27-70(100)81(113)91-52(5)71(84)103)96-75(107)63(25-10-14-39-90-73(105)60-23-17-36-87-48-60)93-74(106)62(24-9-13-38-89-72(104)59-22-16-35-86-47-59)94-80(112)69(49-101)99-79(111)68(45-56-19-15-34-85-46-56)98-78(110)67(43-54-29-32-61(83)33-30-54)97-77(109)66(92-53(6)102)44-55-28-31-57-20-7-8-21-58(57)42-55/h7-8,15-17,19-23,28-36,42,46-48,50-52,62-70,88,101H,9-14,18,24-27,37-41,43-45,49H2,1-6H3,(H2,84,103)(H,89,104)(H,90,105)(H,91,113)(H,92,102)(H,93,106)(H,94,112)(H,95,108)(H,96,107)(H,97,109)(H,98,110)(H,99,111)/t52-,62+,63-,64+,65+,66-,67-,68-,69+,70+/m1/s1
2.1.3 InChI Key
QRYFGTULTGLGHU-NBERXCRTSA-N
2.1.4 Canonical SMILES
CC(C)CC(C(=O)NC(CCCCNC(C)C)C(=O)N1CCCC1C(=O)NC(C)C(=O)N)NC(=O)C(CCCCNC(=O)C2=CN=CC=C2)NC(=O)C(CCCCNC(=O)C3=CN=CC=C3)NC(=O)C(CO)NC(=O)C(CC4=CN=CC=C4)NC(=O)C(CC5=CC=C(C=C5)Cl)NC(=O)C(CC6=CC7=CC=CC=C7C=C6)NC(=O)C
2.1.5 Isomeric SMILES
C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCNC(=O)C2=CN=CC=C2)NC(=O)[C@H](CCCCNC(=O)C3=CN=CC=C3)NC(=O)[C@H](CO)NC(=O)[C@@H](CC4=CN=CC=C4)NC(=O)[C@@H](CC5=CC=C(C=C5)Cl)NC(=O)[C@@H](CC6=CC7=CC=CC=C7C=C6)NC(=O)C
2.2 Other Identifiers
2.2.1 UNII
94055UOQ3Y
2.3 Synonyms
2.3.1 MeSH Synonyms

1. A8802 Compound

2. Iturelix

3. N-ac-nal(1)-4-cl-phe(2)-pal(3)-nic-lys(5)-nic-lys(6)-leu(7)-i-lys(8)-pro(9)-ala(10)-nh2

4. N-ac-nal(1)-4-cl-phe(2)-pal(3)-ser(4)-nic-lys(5)-nic-lys(6)-leu(7)-i-lys(8)-pro(9)-ala(10)-nh2

5. Nal-lys-gnrh

6. Nal-lys-gnrhant

7. Orf 23541

8. Orf-23541

2.3.2 Depositor-Supplied Synonyms

1. Iturelix

2. 112568-12-4

3. Orf 23541

4. Nal-lys Anatagonist

5. Orf-32541

6. Antide Acetate

7. 94055uoq3y

8. Nal-lys-gnrhant

9. (n-acetyl-3-(naphhalen-2-yl)-d-alanyl)-p-chloro-d-phenylalanyl-3-(3-pyridyl)-d-alanyl-l-seryl-n(sup 6)-nicotinyl-l-lysyl-n(sup 6)-nicotinyl-d-lysyl-l-leucyl-n(sup 6)-isopropyl-l-lysyl-l-prolyl-d-alaninamide

10. Nal-lys-gnrh

11. D-alaninamide, N-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-n6-(3-pyridinylcarbonyl)-l-lysyl-n6-(3-pyridinylcarbonyl)-d-lysyl-l-leucyl-n6-(1-meth Ylethyl)-l-lysyl-l-prolyl-

12. Orf-23541

13. Iturelix [usan:inn]

14. Brn 4866881

15. Unii-94055uoq3y

16. Iturelix [usan]

17. Iturelix [inn]

18. Iturelix [who-dd]

19. D-alaninamide, N-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-n6-(3-pyridinylcarbonyl)-l-lysyl-n6-(3-pyridinylcarbonyl)-d-lysyl-l-leucyl-n6-(1-methylethyl)-l-lysyl-l-prolyl-

20. N-ac-nal(1)-4-cl-phe(2)-pal(3)-ser(4)-nic-lys(5)-nic-lys(6)-leu(7)-i-lys(8)-pro(9)-ala(10)-nh2

21. Gtpl3854

22. Schembl1649367

23. Chembl3989438

24. Dtxsid201033848

25. Akos015896023

26. D-alaninamide, N-acetyl-3-(2-naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-n(sup 6)-(3-pyridinylcarbonyl)-l-lysyl-n(sup 6)-(3-pyridinylcarbonyl)-d-lysyl-l-leucyl-n(sup 6)-(1-methylethyl)-l-lysyl-l-prolyl-

27. D-alaninamide, N-acetyl-3-(naphthalenyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridinyl)-d-alanyl-l-seryl-n(sup 6)-3-pyridinylcarbonyl)-l-lysyl-n(sup 6)-(3-pyridinylcarbonyl)-d-lysyl-l-leucyl-n(sup 6)-(1-methylethyl)-l-lysyl-l-prolyl-

28. 568a124

29. D 21074

30. Q27888363

31. N-acetyl-3-(2-naphthyl)-d-alanyl-4-chloro-d-phenylalanyl-3-(3-pyridyl)-d-alanyl-l-seryl-n6-nicotinoyl-l-lysyl-n6-nicotinoyl-d-lysyl-l-leucyl-n6-isopropyl-l-lysyl-l-prolyl-d-alaninamide

2.4 Create Date
2007-07-03
3 Chemical and Physical Properties
Molecular Weight 1591.3 g/mol
Molecular Formula C82H108ClN17O14
XLogP35
Hydrogen Bond Donor Count14
Hydrogen Bond Acceptor Count18
Rotatable Bond Count46
Exact Mass1589.7950189 g/mol
Monoisotopic Mass1589.7950189 g/mol
Topological Polar Surface Area454 Ų
Heavy Atom Count114
Formal Charge0
Complexity3110
Isotope Atom Count0
Defined Atom Stereocenter Count10
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Hormone Antagonists

Chemical substances which inhibit the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. (See all compounds classified as Hormone Antagonists.)


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty